Becton, Dickinson and Company (NYSE:BDX) to Issue Quarterly Dividend of $0.95

Becton, Dickinson and Company (NYSE:BDXGet Free Report) declared a quarterly dividend on Tuesday, January 23rd, RTT News reports. Investors of record on Friday, March 8th will be given a dividend of 0.95 per share by the medical instruments supplier on Friday, March 29th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date of this dividend is Thursday, March 7th.

Becton, Dickinson and Company has raised its dividend payment by an average of 4.8% annually over the last three years and has increased its dividend annually for the last 52 consecutive years. Becton, Dickinson and Company has a dividend payout ratio of 26.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect Becton, Dickinson and Company to earn $14.31 per share next year, which means the company should continue to be able to cover its $3.80 annual dividend with an expected future payout ratio of 26.6%.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $233.57 on Wednesday. Becton, Dickinson and Company has a 52-week low of $228.62 and a 52-week high of $287.32. The company has a 50-day simple moving average of $239.36 and a 200 day simple moving average of $248.91. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The company has a market capitalization of $67.48 billion, a PE ratio of 55.35, a price-to-earnings-growth ratio of 1.95 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.73 billion. During the same period in the previous year, the business posted $2.98 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. On average, research analysts predict that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Barclays upped their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Raymond James boosted their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley reduced their price objective on shares of Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating on the stock in a research report on Monday, December 4th. TheStreet downgraded shares of Becton, Dickinson and Company from a “b” rating to a “c+” rating in a research report on Thursday, November 9th. Finally, Piper Sandler reduced their target price on shares of Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

Check Out Our Latest Research Report on Becton, Dickinson and Company

Hedge Funds Weigh In On Becton, Dickinson and Company

Several hedge funds and other institutional investors have recently bought and sold shares of BDX. Moneta Group Investment Advisors LLC lifted its stake in Becton, Dickinson and Company by 95,813.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock valued at $1,028,807,000 after acquiring an additional 4,041,425 shares during the period. Norges Bank bought a new position in Becton, Dickinson and Company during the 4th quarter valued at about $697,398,000. Legal & General Group Plc lifted its stake in shares of Becton, Dickinson and Company by 17.4% in the 4th quarter. Legal & General Group Plc now owns 2,438,838 shares of the medical instruments supplier’s stock worth $594,662,000 after purchasing an additional 362,285 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,012,078 shares of the medical instruments supplier’s stock worth $269,213,000 after purchasing an additional 333,546 shares during the period. Finally, Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $28,886,000. Institutional investors own 86.72% of the company’s stock.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Dividend History for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.